Acrotech Biopharma’s $300 Million Acquisition of Spectrum Pharmaceuticals’ Hematology/Oncology Portfolio

Paul Hastings advised Spectrum Pharmaceuticals, Inc. on the deal

Spectrum Pharmaceuticals, Inc. executed the sale of seven FDA-approved hematology/oncology products to Acrotech Biopharma LLC, a subsidiary of Aurobindo Pharma USA, Inc., for up to $300 million.

Spectrum Pharmaceuticals, Inc. is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The company, led by Joseph W Turgeon, Francois Lebel and Kurt A Gustafson, in 2018 recorded $109 Million Revenues.

Corporate Partner Carl R. Sanchez (Picture) in San Diego led the Paul Hastings team, which also included associates Spencer Young, Tyler Dodge and Philip Dodd.

Involved fees earner: Philip Dodd – Paul Hastings; Tyler Dodge – Paul Hastings; Carl Sanchez – Paul Hastings; Spencer Young – Paul Hastings;

Law Firms: Paul Hastings;

Clients: Spectrum Pharmaceuticals Inc.;


Author: Ambrogio Visconti